Biomoda,
Inc. is focused on the development and commercialization of
cost-effective, non-invasive, accurate and reproducible
diagnostic assays for the early detection of cancer. Our
mission is to save lives by making the early diagnosis of the
deadliest cancers available at an affordable cost to large
populations worldwide.
Based on
molecular marker technology developed at Los Alamos National
Laboratory and trademarked under the name CyPath®, Biomoda’s
initial product targets lung cancer.
The CyPath® diagnostic
is currently in clinical trials and can be used only for
investigational purposes. Results of the current study and
additional clinical trials will be submitted to the U.S. Food
and Drug Administration (FDA) as required prior to approval for
commercial use. If approved by the FDA, Biomoda’s
simple, non-invasive in-vitro test for early detection of lung
cancer is expected to provide compelling value to the healthcare
system through cost savings and improved patient outcomes.
Biomoda is
publicly traded under the symbol BMOD. Current research and
development operations, laboratory functions for both microscopy
and assay formulation, and administrative offices are located at
609 Broadway NE in Albuquerque, NM, in a LEEDS-certified
building.
Biomoda
Presents To Health Care Industry in San Francisco
|
This website contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking
statements are based on estimates, projections, beliefs
and assumptions of Biomoda management at the time of
such statements and are not guarantees of future
performance. Forward-looking
statements involve risks and uncertainties in predicting
future results and conditions. Actual results could
differ materially from those projected in these
forward-looking statements due to a variety of factors,
including, without limitation, the acceptance by
customers of our products, our ability to develop new
products cost-effectively, our ability to raise capital
in the future, the development by competitors of
products using improved or alternative technology, the
retention of key employees and general economic
conditions. Forward-looking
statements are subject to change without notice. |
|
